<DOC>
	<DOC>NCT00892281</DOC>
	<brief_summary>The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.</brief_summary>
	<brief_title>ORCA - Oracea® for Rosacea: A Community-based Assessment</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Males and females aged 18 and older Subjects with diagnosis of rosacea (IGA of 2 to 4) Subjects who used a topical or systemic acne treatment within 4 months of the baseline visit (retinoids and isotretinoin) Subjects who used a topical or systemic antibiotic within 4 weeks of the baseline visit Subjects who had laser or IPL (intense pulsed light) treatments within 3 months of the baseline visit and/or who plan to have these treatments during the study Subjects who have a known hypersensitivity to tetracyclines or ingredients of the add on medications Subjects who have stomach or GI problems, kidney disease or have an active systemic fungal infection or a vaginal yeast infection are excluded</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>